NKTR Stock — Nektar Therapeutics

Nektar Therapeutics (NKTR)

Updated October 16, 2026.

NKTR is a Stock. Total return is -36.4% over the past 32.5 years, 2921.1 points behind SPY at 2884.7%.

Nektar Therapeutics is a biopharmaceutical company developing immunotherapy medicines, with a pipeline focused on treating autoimmune disorders, inflammatory diseases, fibrotic conditions, and certain cancers through programs such as rezpegaldesleukin and NKTR-0165. The company maintains collaboration agreements with major pharmaceutical partners including AstraZeneca, Roche, Pfizer, and Bristol-Myers Squibb. Nektar does not currently have an established distribution schedule.

NKTR performance versus SPY

Price and return data through 2026-10-16.

Total return is -36.4% over the past 32.5 years, 2921.1 points behind SPY at 2884.7%. Over the past year its total return — price change plus distributions reinvested — is -34.9%. Its deepest 1-year drawdown was 64.3%.

NKTR key facts

Asset type

Stock

Asset class

Equity

Inception date

05/03/1994

Distribution frequency

None

Last close

$35.78 (as of 2026-10-16)

Market cap

$1,221,636,325

Average volume

784232.0

Beta

1.273

Payout ratio

0.0%

Forward P/E

34.0136

EPS

$-18.96

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NKTR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.3%.

Who may consider NKTR — and who may not

It is a weaker fit for investors who need monthly cash flow (NKTR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NKTR

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions